Core Viewpoint - Jingtai Holdings (02228) experienced a significant stock increase of over 6%, reaching HKD 11.4 with a trading volume of HKD 41.9461 million, following the announcement of a strategic collaboration with Eli Lilly valued at up to USD 345 million [1] Group 1: Strategic Collaboration - Jingtai Technology's wholly-owned subsidiary Ailux has entered into a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value potentially reaching USD 345 million, including several million dollars in upfront payments and milestone payments [1] - This collaboration aims to leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas, while also utilizing its AI antibody research platform to enhance internal pipeline research [1] Group 2: Previous Collaborations - This agreement follows a previous collaboration in 2023, where Jingtai Technology and Eli Lilly signed a USD 250 million partnership focused on AI small molecule drugs, indicating a continued partnership between the two companies [1] Group 3: Ailux Development - Ailux, which has been a key focus for Jingtai Technology since 2021, has rapidly developed and commercialized its large molecule drug research platform over the past two years [1] - The platform employs a hybrid research model that combines AI-driven antibody drug design and engineering, effectively addressing the challenges of high costs and long timelines in drug discovery, enabling pharmaceutical companies to explore diverse targeting mechanisms and differentiated drug development pathways [1] - Ailux is expected to advance AI-designed next-generation antibody drugs into later clinical stages, aiming for more impactful major commercial collaborations in the future [1]
港股异动 | 晶泰控股(02228)高开逾6% 就AI赋能双特异性抗体与礼来达成3.45亿美元平台战略合作